Literature DB >> 35179606

Characterization of the Mechanistic Linkages Between Iodothyronine Deiodinase Inhibition and Impaired Thyroid-Mediated Growth and Development in Xenopus laevis Using Iopanoic Acid.

Jonathan T Haselman1, Jennifer H Olker1, Patricia A Kosian1, Joseph J Korte1, Jeffrey S Denny1, Joseph E Tietge1, Michael W Hornung1, Sigmund J Degitz1.   

Abstract

Iodothyronine deiodinases (DIO) are key enzymes that influence tissue-specific thyroid hormone levels during thyroid-mediated amphibian metamorphosis. Within the larger context of evaluating chemicals for thyroid system disrupting potential, chemical activity toward DIOs is being evaluated using high-throughput in vitro screening assays as part of U.S. EPA's ToxCast program. However, existing data gaps preclude any inferences between in vitro chemical inhibition of DIOs and in vivo outcomes relevant to ecological risk assessment. This study aimed to generate targeted data in a laboratory model species (Xenopus laevis) using a model DIO inhibitor, iopanoic acid (IOP), to characterize linkages between in vitro potency, in vivo biochemical responses, and adverse organismal outcomes. In vitro potency of IOP toward DIOs was evaluated using previously developed in vitro screening assays, which showed concentration-dependent inhibition of human DIO1 (IC50: 97 µM) and DIO2 (IC50: 231 µM) but did not inhibit human or X. laevis DIO3 under the assay conditions. In vivo exposure of larval X. laevis to 0, 2.6, 5.3, and 10.5 µM IOP caused thyroid-related biochemical profiles in the thyroid gland and plasma consistent with hyperthyroxinemia but resulted in delayed metamorphosis and significantly reduced growth in the highest 2 exposure concentrations. Independent evaluations of dio gene expression ontogeny, together with existing literature, supported interpretation of IOP-mediated effects resulting in a proposed adverse outcome pathway for DIO2 inhibition leading to altered amphibian metamorphosis. This study highlights the types of mechanistic data needed to move toward predicting in vivo outcomes of regulatory concern from in vitro bioactivity data. Published by Oxford University Press on behalf of the Society of Toxicology 2022. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Keywords:  zzm321990 Xenopus laeviszzm321990 ; adverse outcome pathway; endocrine disruption; iodothyronine deiodinase; thyroid

Mesh:

Substances:

Year:  2022        PMID: 35179606      PMCID: PMC9254162          DOI: 10.1093/toxsci/kfac014

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.109


  37 in total

1.  The role of 3,5,3'-triiodothyronine in the physiological action of thyroxine in the premetamorphic tadpole.

Authors:  V A Galton
Journal:  Endocrinology       Date:  1989-05       Impact factor: 4.736

2.  Screening the ToxCast Phase 1, Phase 2, and e1k Chemical Libraries for Inhibitors of Iodothyronine Deiodinases.

Authors:  Jennifer H Olker; Joseph J Korte; Jeffrey S Denny; Phillip C Hartig; Mary C Cardon; Carsten N Knutsen; Paige M Kent; Jessica P Christensen; Sigmund J Degitz; Michael W Hornung
Journal:  Toxicol Sci       Date:  2019-04-01       Impact factor: 4.849

3.  Targeted Pathway-based In Vivo Testing Using Thyroperoxidase Inhibition to Evaluate Plasma Thyroxine as a Surrogate Metric of Metamorphic Success in Model Amphibian Xenopus laevis.

Authors:  Jonathan T Haselman; Jennifer H Olker; Patricia A Kosian; Joseph J Korte; Joseph A Swintek; Jeffrey S Denny; John W Nichols; Joseph E Tietge; Michael W Hornung; Sigmund J Degitz
Journal:  Toxicol Sci       Date:  2020-06-01       Impact factor: 4.849

4.  Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein.

Authors:  P H Eng; G R Cardona; S L Fang; M Previti; S Alex; N Carrasco; W W Chin; L E Braverman
Journal:  Endocrinology       Date:  1999-08       Impact factor: 4.736

5.  An Improved Nonradioactive Screening Method Identifies Genistein and Xanthohumol as Potent Inhibitors of Iodothyronine Deiodinases.

Authors:  Kostja Renko; Sonja Schäche; Carolin S Hoefig; Tim Welsink; Christian Schwiebert; Doreen Braun; Niels-Peter Becker; Josef Köhrle; Lutz Schomburg
Journal:  Thyroid       Date:  2015-06-25       Impact factor: 6.568

6.  Expression of type II iodothyronine deiodinase marks the time that a tissue responds to thyroid hormone-induced metamorphosis in Xenopus laevis.

Authors:  Liquan Cai; Donald D Brown
Journal:  Dev Biol       Date:  2004-02-01       Impact factor: 3.582

7.  Inhibition of the thyroid hormone pathway in Xenopus laevis by 2-mercaptobenzothiazole.

Authors:  Joseph E Tietge; Sigmund J Degitz; Jonathan T Haselman; Brian C Butterworth; Joseph J Korte; Patricia A Kosian; Annelie J Lindberg-Livingston; Emily M Burgess; Pamela E Blackshear; Michael W Hornung
Journal:  Aquat Toxicol       Date:  2012-10-29       Impact factor: 4.964

8.  Expanded high-throughput screening and chemotype-enrichment analysis of the phase II: e1k ToxCast library for human sodium-iodide symporter (NIS) inhibition.

Authors:  Jun Wang; Ann M Richard; Ashley S Murr; Angela R Buckalew; Ryan R Lougee; Mahmoud Shobair; Daniel R Hallinger; Susan C Laws; Tammy E Stoker
Journal:  Arch Toxicol       Date:  2021-03-03       Impact factor: 6.168

9.  Xenopus laevis and human type 3 iodothyronine deiodinase enzyme cross-species sensitivity to inhibition by ToxCast chemicals.

Authors:  Sally A Mayasich; Joseph J Korte; Jeffrey S Denny; Phillip C Hartig; Jennifer H Olker; Philip DeGoey; Joseph O'Flanagan; Sigmund J Degitz; Michael W Hornung
Journal:  Toxicol In Vitro       Date:  2021-03-11       Impact factor: 3.685

10.  Evaluating Chemicals for Thyroid Disruption: Opportunities and Challenges with in Vitro Testing and Adverse Outcome Pathway Approaches.

Authors:  Pamela D Noyes; Katie Paul Friedman; Patience Browne; Jonathan T Haselman; Mary E Gilbert; Michael W Hornung; Stan Barone; Kevin M Crofton; Susan C Laws; Tammy E Stoker; Steven O Simmons; Joseph E Tietge; Sigmund J Degitz
Journal:  Environ Health Perspect       Date:  2019-09-05       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.